All In MedTech

FDA Clearance Tracker · P120023-S004

KAMRA INLAY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 16, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 16, 2017

Approved

Time to decision

230 days

Received Sep 28, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P120023-S004
Device name
KAMRA INLAY
Applicant
Corneagen
Applicant location
Seattle, WA
Received
Sep 28, 2016
Decided
May 16, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P120023

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LQE

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Corneagen

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.